Business

MASS. MOVERS

Amag results expected to come up short

ISTOCKPHOTO.COM
Advertisement

Amag Pharmaceuticals Inc. slumped on preliminary fourth-quarter revenue of between $14.3 million and $15 million, lower than the $16 million analysts had estimated. The Lexington company put itself up for sale late last year after lackluster revenue for its anemia drug and a failed merger bid. It received approval for Feraheme from Canadian regulators in December. Amag said it expects fourth-quarter operating costs and expenses of $38 million to $43 million, including restructuring costs and a $2 million termination fee to Allos Therapeutics.